Enanta Pharmaceuticals (ENTA) Shareholder's Equity Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.19% |
| Dec 31, 2025 | -22.47% |
| Sep 30, 2025 | -32.32% |
| Jun 30, 2025 | -30.26% |
| Mar 31, 2025 | -28.08% |
| Dec 31, 2024 | -25.35% |
| Sep 30, 2024 | -22.56% |
| Jun 30, 2024 | -19.77% |
| Mar 31, 2024 | -17.56% |
| Dec 31, 2023 | -14.78% |
| Sep 30, 2023 | -11.25% |
| Jun 30, 2023 | -8.00% |
| Mar 31, 2023 | -4.18% |
| Dec 31, 2022 | -1.08% |
| Sep 30, 2022 | 1.27% |
| Jun 30, 2022 | 5.32% |
| Mar 31, 2022 | 6.15% |
| Dec 31, 2021 | 7.47% |
| Sep 30, 2021 | 8.15% |
| Jun 30, 2021 | 9.21% |
| Mar 31, 2021 | 10.35% |
| Dec 31, 2020 | 11.33% |
| Sep 30, 2020 | 14.04% |
| Jun 30, 2020 | 16.05% |
| Mar 31, 2020 | 16.73% |
| Dec 31, 2019 | 20.01% |
| Sep 30, 2019 | 25.48% |
| Jun 30, 2019 | 23.98% |
| Mar 31, 2019 | 33.80% |
| Dec 31, 2018 | 32.23% |
| Sep 30, 2018 | 28.94% |
| Jun 30, 2018 | 25.83% |
| Mar 31, 2018 | 23.01% |
| Sep 30, 2017 | 35.78% |